Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Common Equity (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Common Equity for 4 consecutive years, with $246.9 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 245.25% to $246.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $246.9 million through Dec 2025, up 245.25% year-over-year, with the annual reading at $246.9 million for FY2025, 245.25% up from the prior year.
  • Common Equity hit $246.9 million in Q4 2025 for Taysha Gene Therapies, up from $219.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $248.7 million in Q2 2025 to a low of -$49.1 million in Q3 2023.
  • Historically, Common Equity has averaged $72.6 million across 4 years, with a median of $54.5 million in 2024.
  • Biggest YoY gain for Common Equity was 7796.42% in 2023; the steepest drop was 558.88% in 2023.
  • Year by year, Common Equity stood at $949000.0 in 2022, then surged by 7796.42% to $74.9 million in 2023, then decreased by 4.55% to $71.5 million in 2024, then surged by 245.25% to $246.9 million in 2025.
  • Business Quant data shows Common Equity for TSHA at $246.9 million in Q4 2025, $219.0 million in Q3 2025, and $248.7 million in Q2 2025.